Finch Therapeutics Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FNCH research report →
About the company
Finch Therapeutics is a microbiome technology company with a portfolio of intellectual property and microbiome assets. The company is now focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations after winding down development efforts.
- CEO
- Matthew Blischak
- IPO
- 2021
- Employees
- 1
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $13.97M
- P/E
- -1.01
- P/S
- 0.00
- P/B
- 1.54
- EV/EBITDA
- -2.30
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -86.83%
- ROIC
- -38.62%
- Revenue
- $0 · -100.00%
- Net Income
- $-13,877,000 · 81.44%
- EPS
- $-8.64 · 81.46%
- Op Income
- $-18,859,000
- FCF YoY
- 0.00%
- 52W High
- $16.10
- 52W Low
- $2.00
- 50D MA
- $12.77
- 200D MA
- $12.96
- Beta
- 1.48
- Avg Volume
- 3.65K
Get TickerSpark's AI analysis on FNCH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 7, 24 | SMISEK JEFFERY A | other | 383 |
| Jun 7, 24 | SMISEK JEFFERY A | other | 384 |
| May 20, 24 | SMISEK JEFFERY A | other | 3,750 |
| Mar 28, 24 | SMISEK JEFFERY A | sell | 1,600 |
| Mar 28, 24 | SMISEK JEFFERY A | sell | 6,642 |
| Nov 22, 23 | SMISEK JEFFERY A | sell | 1,470 |
| Jun 9, 23 | Blischak Matthew P. | other | 962,899 |
| Jun 8, 23 | Blischak Matthew P. | other | 962,899 |
| Jun 8, 23 | Lange Christian H. | other | 10,000 |
| Jun 8, 23 | SMISEK JEFFERY A | other | 10,000 |
Our FNCH coverage
Recent articles, reports, and earnings notes.
No research on FNCH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FNCH report →Similar companies
Peers in the same neighborhood.